As Novo Nordisk campaigns against counterfeit versions of Ozempic, its Type 2 diabetes drug popularly used for weight loss, one analysis predicts the therapy will log $16.1 billion in sales in 2024, making it the second top-selling drug.
GLP-1s
Hospital transplant departments have strict cutoffs for patients with higher body mass indexes because of the increased risk of complications, but GLP-1s such as Ozempic and Wegovy are helping more patients be eligible for surgery.
Counterfeit versions of Novo Nordisk's Ozempic are becoming more of a concern, both for the company and to global authorities. Lars Fruergaard Jørgensen, the Danish drugmaker's CEO, told Reuter's the company is currently working alongside authorities in multiple countries to…
Citing high costs and low medication adherence, self-insured employers nationwide are making moves to end or limit coverage for employees prescribed weight loss medications, including major health systems.
New York City Councilwoman Julie Menin introduced a bill March 7 that would require the city's Commissioner of Health and Mental Hygiene to create and distribute materials about the possible negative health effects from prescribing and using prescription drugs for their…
Advertisement
After finding success in the emerging sector of semaglutide drugs, Novo Nordisk's latest work toward development of it in pill form has shown results that are even better than Wegovy when it comes to shedding weight.
Physicians are reportedly seeing an increasing number of patients who have used anti-obesity drugs like Ozempic and Wegovy request procedures to remove sagging, excess skin via plastic surgery, KDVR reported Feb. 23.